Who makes Agomelatine or PIacebo?

Agomelatine or PIacebo is developed by Second Affiliated Hospital of Soochow University.

What development phase is Agomelatine or PIacebo in?

Agomelatine or PIacebo is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Agomelatine or PIacebo

Second Affiliated Hospital of Soochow University · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	Agomelatine or PIacebo
Also known as	Pramipexole
Sponsor	Second Affiliated Hospital of Soochow University
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

the Efficacy and Safety of Agomelatine in the Patients With Parkinson's Disease (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Agomelatine or PIacebo CI brief — competitive landscape report
Agomelatine or PIacebo updates RSS · CI watch RSS
Second Affiliated Hospital of Soochow University portfolio CI